Novo Nordisk has made a bold offer to buy Metsera Therapeutics for $6.5 billion, but the final decision rests with Metsera’s board. Earlier, Pfizer bought Metsera for $4.9 billion, making Novo Nordisk’s offer a significant challenge in the competitive obesity drug market, where Eli Lilly is also a key player. Pfizer has turned down Novo Nordisk’s offer, claiming it’s an attempt to stifle competition. Novo’s offer is still under review by Metsera’s board. Initially, Metsera chose Pfizer because it could complete the deal quickly and confidently. Jay Patel, a pharmaceutical expert, believes this competition shows how valuable Metsera’s drug pipeline is, especially its promising obesity drug MET-097i. Novo Nordisk might be trying to boost its position after losing market share to Eli Lilly and facing setbacks in its own drug development. Meanwhile, Pfizer is under pressure after its own obesity drug failed. The final decision will depend on whether Pfizer can make a better offer or if Metsera’s board prefers Novo Nordisk’s offer despite the legal risks.